Research
Hormonal
Targeting amylin receptors improves weight control and may act additively with other treatments.
Combining treatments targeting amylin receptors may enhance obesity management strategies.
StrongSupportsmedium confidence
There is increasing evidence that targeting the amylin receptors (AMYRs) improves weight control and has the potential to act additively with other treatments such as glucagon-like peptide-1 receptor agonists.
Why this rating
The claim is based on existing evidence regarding amylin receptors.
Source
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher et al. · Journal of Pharmacology and Experimental Therapeutics · 2021
DOI 10.1124/jpet.121.000567
otherCited 65×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →